Clinical trial
A Multi-Center, Two-Stage, Open-Label Phase I and Randomized, Active Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology Compared With Eylea for the Treatment of Recurrent CNV Secondary to AMD
NCT02228304 is registered in ClinicalTrials.gov with Neurotech Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Center, Two-Stage, Open-Label Phase I and Randomized, Active Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology Compared With Eylea for the Treatment of Recurrent CNV Secondary to AMD
- Lead sponsor
- Neurotech Pharmaceuticals
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- September 30, 2014
- Completion date
- April 30, 2016
- Enrollment
- 42 (actual)
- Sites
- 38
Conditions
As the registry lists them; a condition with its own page is linked.